Myopia or nearsightedness is characterized as an individual unable to see well at distance in one or both eyes. For example, your child is in the classroom and is unable to see the letters MYOPIA MANAGEMENT on the smart board. The cause of this blurriness is that the child’s eyes are lengthening or elongating, which causes objects at a distance to become blurrier.
At first, your eye doctor may recommend eyeglasses or contact lenses to improve your vision at distance. This will solve the immediate problem of blurriness; however, a younger child can expect an increase in the prescription for subsequent years. To limit or reduce that change, eye doctors often recommend myopia management tools. Myopia management is the treatment of nearsightedness or myopia to limit or reduce the rate of change of nearsightedness or myopia in a child. Reducing the rate of change in your child’s prescription has positive impacts on eye and vision health in the long-term.
As you scroll on the myopia simulator, you will see negative values or numbers. These numbers indicate the levels of nearsightedness.
Launch Myopia Simulator
The most common solution or correction are prescribed glasses or contact lenses; however, new research and development has created additional evidence-based treatment options to decrease the advancement of myopia or nearsightedness.
There are many factors that cause the increase of nearsightedness, but there are lifestyle changes that can be implemented to reduce risk.
Speak with your eye doctor for any additional recommendations.
When your eye doctor prescribes eyeglasses, it is important to wear them recommended by your eye doctor. Children that are nearsighted should wear their glasses full time. Research studies show young children wearing glasses full time show less prescription change the subsequent year compared to those who did not wear their glasses full time.
In addition, your eye doctor may recommend lined or no-line bifocals (progressives), as some studies show a decrease rate of progression of nearsightedness.
Low dose atropine has been studied through several studies known as Atropine in the Treatment of Myopia (ATOM 1), Atropine in the Treatment of Myopia (ATOM 2), and Low-Concentration Atropine for Myopia (LAMP) studies. It is commonly known that topical Atropine has side effects of blurred vision at near (affecting the focusing mechanism of the eye) and increased light sensitivity (pupil dilated). While rare, systemic side effects could take place, but are extremely rare for topical (eye drop) applications.
ATOM 1 studied atropine 1% with an outcome of reducing myopia progression and axial elongation (how long the eyeball grows).
ATOM 2 studied different levels of atropine. Atropine 0.01% was determined to be the most optimal concentration with the least amount of side effects for patients in the research studies.
LAMP studied two specific concentrations of atropine between 0.01% and 0.05%. The double-blinded, randomized placebo-controlled study concluded that 0.05% was most effective concentration with the least amount of side effects.
Overall, talk with your eye doctor to determine if low dose atropine could be an option.
MiSight® 1 day contacts lenses are specifically designed daily disposable contact lenses engineered to reduce nearsightedness or myopia that has been FDA approved for children aged from 8-12.
The contact lenses are approved for children from the age of 8-12 years of age. These contact lenses are used for nearsightedness or myopia (negative refractive error).
Higher levels of nearsightedness has exclusions and different levels of astigmatism. The child must be between -0.75 and -4.00D for the spherical component of the prescription; however, the contact lenses go up to -6.00D. There are limitations for patients with astigmatism correction, but it is recommended to speak to your eye doctor.
MiSight®1 day lenses have multiple treatment zones that change how the light is distributed on the back part of the eye known as the retina. Below, there are four separate zones. The treatment zone aligns focused light in FRONT of the back of the eye, which has been proven to decrease the lengthening of the back of the eye. The correction zone allows light to focus on the BACK part of the eye allowing clear, comfortable vision for the wearer.
The study required a minimum of 6 days of wear each week and to be worn 12 hours daily.
The typical recommended visits are as follows:
Visits | Expectations |
---|---|
Comprehensive Eye Examination | Baseline eye and vision health tests |
Myopia Discussion (within 6 months of eye exam) | Conversation regarding options |
Contact Lens Class (Insertion/Removal) | Approximately 1 hour - Must place and remove contact lenses in order to take contact lenses home |
1 Week Follow-up (10-20 minutes) | Your eye doctor will check for any eye concerns due to contact lenses. |
1 Month Follow-up (10-20 minutes) | Your eye doctor ensures proper fit. |
6 Month Follow-up (10-30 minutes) | Your eye doctor will check for any change in prescription power and will update as needed. |
The typical recommended visit frequency is twice a year, but this may change based upon each patient’s unique eye and vision needs.
Complications can arise, but proper care and wear is important to reduce or minimize these risks. Work with your eye doctor to ensure you are taking proper care of your contact lenses.
At the present time, the research studies show that myopia continues to increase at least to age 15 in the present MiSight®1 day lens studies. Therefore, it is important to continue treatment or discuss with your eye doctor your options.
Orthokeratology lenses are rigid gas permeable lenses that are placed on the front surface of the eye prior to bed time each night. The contact lens reshapes the cornea (front surface of the eye) consistent with the treatment needed to allow for clear vision during the day without wearing contact lenses. Please talk with your eye doctor to determine if this option is right for you! Check out a video by Dr. Joseph Allen or Doctor Eye Health show to learn more!
Approximately 20 million children in the United States have been diagnosed with myopia. By 2050, it is predicted that at least 50% of the world’s population will be myopic. In the last two generations, myopia has increased from 25% to 42%.
Yes, genes or the genetic makeup of everyone does play a role in the presence or progression of myopia in young people. In twin studies, research shows an up to 90% link with genetics between twin siblings. If one or both parents are nearsighted, it increases the risk that your children will be as well (the risk is even greater with both parents).
Myopia management is important for the overall eye health of children. There are simple recommendations your eye doctor can provide or more sophisticated management tools (specific contacts, medications, etc.) that can be implemented to improve the health of your child’s eye and vision health. Speak with your eye doctor at your next appointment to learn more!
The study shows approximately 66% reduction of myopia over time. This assumes that all instructions are being followed like the clinical trial of LAMP.
The table below gives a typical outlook for follow-ups recommended in the first year. This follow-up schedule can change depending on the needs of each child.
Exams/Follow-Ups | Brief Overview of Visit |
---|---|
Comprehensive Eye Examination | - Complete eye and vision health assessment |
Myopia Management Consult (30 min) | - Discussion on the therapy in office |
3 months (15-30 min) | - Check for change in vision |
6 months (30 min-1 hr) | - Check for change in vision - Refraction completed |
9 months (15-30 min) | - Check for change in vision |
1 year - Comprehensive Eye Examination | - Complete eye and vision health assessment |
Exams/Follow-Ups | Brief Overview of Visit |
---|---|
Comprehensive Eye Examination | - Complete eye and vision health assessment |
4 months | - Check for change in vision |
6-8 months (30 min-1 hr) | - Check for change invision - Refraction completed |
1 year - Comprehensive Eye Examination | - Complete eye and vision health assessment |
No, medical or vision plans do not cover the cost of these evaluations. As of now, medical policies do not consider refractive change a disease process.
No, the cost of compounded atropine 0.05% is not covered by medical insurance. The typical cost is around $75-100.00 for a three-month supply.